Corporation announced that the Company closed the subscription period of its previously announced rights offering at 5:00 PM ...

CytoSorbents (NASDAQ:CTSO) has announced preliminary Q4 and full-year 2024 financial results. The company estimates Q4 product revenue between $9.0 million-$9.2 million vs. consensus of $9.45M, ...

Oversubscribed Rights Offering Generated $6.25 Million in Aggregate Gross Proceeds Offering Proceeds Satisfies Debt Covenant, ...

Cytosorbents ( (CTSO) ) has shared an update. CytoSorbents Corporation successfully closed an oversubscribed rights offering, raising $6.25 million in aggregate gross proceeds, which satisfies a debt ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $8.71, a high ...

D. Boral Capital says CytoSorbents (CTSO) reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The ...

Fourth quarter product revenue is estimated to be in the range of $9M to $9.2M, representing 22% to 25% growth versus $7.35 million in the ...

3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Presbia has higher earnings, but lower revenue than Cytosorbents. Presbia has a beta of 5.91 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Offering Proceeds Satisfies Debt Covenant, Unlocking $5.0 Million in Restricted Cash Currently on the Balance Sheet PRINCETON, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation ...

D. Boral Capital says CytoSorbents (CTSO) reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The company also demonstrated a significant gross margin ...